Breakthrough Vaccine Targets Future Pandemics by Neutralizing Unknown Coronaviruses

Developed by a collaborative team from Oxford, Cambridge, and Caltech, the new vaccine employs innovative technology to preemptively combat potential viral threats.

The vaccine focuses on sarbecoviruses, including those responsible for COVID-19, SARS, and potential future strains.
Utilizes 'protein superglue' to combine multiple viral components, enhancing its ability to preempt unknown viruses.
Proven effective in mice, the vaccine generates broad immune responses, even in subjects previously exposed to SARS-CoV-2.
Streamlined production process promises easier and faster large-scale manufacturing.
Next steps include human trials and expanding the technology to other virus families with pandemic potential.